Merck has reported results for the third quarter ended September 30, 2013.
The company has reported 38.88% fall in its net profit at Rs 15.77 crore for the quarter as compared to Rs 25.80 crore for the same quarter in the previous year. However, total income from operations of the company has increased by 10.39% at Rs 207.47 crore for quarter under review as compared to Rs 187.95 crore for the quarter ended September 30, 2012.
Merck is a global pharmaceutical and chemical enterprise. In the pharmaceutical segment major products include vitamins, nutritional supplement, cardio vascular, respiratory, hematinics, cough and cold, non-steroidal anti-inflammatory (NSAID), antibiotics, oral rehydration salts and encephalotropics.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: